Alexa Fluor® 568 Anti-CD33 antibody [EPR23051-101],Abcam,AB313027

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Target Binding Affinity, Antibody Labelling, ICC/IF, IHC-P

Conjugate

Alexa Fluor® 568

Platform ID

BAB107781327

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAlexa Fluor® 568 Anti-CD33 antibody [EPR23051-101]
Cat. No.AB313027
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAlexa Fluor® 568
ApplicationTarget Binding Affinity, Antibody Labelling, ICC/IF, IHC-P
ClonalityMonoclonal
Clone NumberEPR23051-101
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed : 10611343, PubMed : 11320212, PubMed : 15597323). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed : 7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed : 10887109, PubMed : 28325905). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed : 10206955, PubMed : 10556798, PubMed : 10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed : 10206955, PubMed : 10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed : 15597323). See full target information CD33

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.